Janagliflozin - Sihuan Pharmaceutical Holdings Group

Drug Profile

Janagliflozin - Sihuan Pharmaceutical Holdings Group

Alternative Names: SGLT2 inhibitor - Sihuan

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group
  • Class Antihypercalcaemics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2016 Phase-I clinical trials in Type-2 diabetes mellitus in China (unspecified route) before December 2016
  • 01 Jul 2014 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route)
  • 01 Jul 2014 CFDA approves IND application for janagliflozin in type 1 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top